Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Generalized Pustular Psoriasis and Erythrodermic Psoriasis: 52-Week Results
Yukari Okubo, Yoshinori Umezawa, Shinya Sakurai, Naoki Hoshii, Hidemi Nakagawa, Yukari Okubo, Yoshinori Umezawa, Shinya Sakurai, Naoki Hoshii, Hidemi Nakagawa
Abstract
Introduction: We report an exploratory analysis of the efficacy and safety of certolizumab pegol (CZP) in Japanese patients with generalized pustular psoriasis (GPP) and erythrodermic psoriasis (EP) (NCT03051217).
Methods: Patients ≥ 20 years with GPP or EP were randomized 1:1 to open-label CZP 400 mg every 2 weeks (Q2W) or 200 mg Q2W (400 mg weeks 0/2/4) for 16 weeks; patients who achieved "much improved" or "very much improved" on the Global Improvement Score (GIS; for GPP) or a PASI 50 response (≥ 50% reduction from baseline Psoriasis Area and Severity Index; for EP) continued to week 52. Efficacy outcomes assessed included Clinical Global Impression of Improvement (CGI-I), Dermatology Life Quality Index (DLQI 0/1), and Itch Numeric Rating Scale (INRS 0). GIS and Japanese Dermatological Association (JDA) severity index were assessed in patients with GPP, and PASI and Physician's Global Assessment (PGA) in patients with EP. Treatment-emergent adverse events (TEAEs) were evaluated through weeks 0-52.
Results: Of 22 patients randomized, 19 completed week 52. At week 16, all reported outcomes improved with both CZP doses and were generally maintained through week 52. At week 52, 6/7 GPP and 12/12 EP patients achieved CGI-I response ("improved" or "remission"). Also, 4/7 GPP and 7/12 EP patients achieved DLQI 0/1; 2/7 GPP and 2/12 EP patients achieved INRS 0. Meanwhile, 6/7 patients with GPP achieved GIS response, and JDA severity index was reduced from baseline. We found that 9/12 and 5/12 patients with EP achieved PASI 90 and PGA 0/1, respectively. Overall, three serious TEAEs were reported in three CZP 400 mg Q2W-treated patients.
Conclusion: CZP treatment over 16 weeks improved the signs and symptoms of GPP and EP, and improvements were maintained through week 52. No new safety signals were identified.
Trial registration: ClinicalTrials.gov identifier, NCT03051217.
Keywords: Anti-tumor necrosis factor; Certolizumab pegol; Erythrodermic psoriasis; Generalized pustular psoriasis; Japan.
© 2022. The Author(s).
Figures
References
- Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005;64(Suppl 2):ii18–ii23.
- Boehner A, Navarini AA, Eyerich K. Generalized pustular psoriasis—a model disease for specific targeted immunotherapy, systematic review. Exp Dermatol. 2018;27(10):1067–1077. doi: 10.1111/exd.13699.
- Singh RK, Lee KM, Ucmak D, et al. Erythrodermic psoriasis: pathophysiology and current treatment perspectives. Psoriasis (Auckl) 2016;6:93–104.
- Weigle N, McBane S. Psoriasis. Am Fam Physician. 2013;87(9):626–633.
- Kubota K, Kamijima Y, Sato T, et al. Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database. BMJ Open. 2015;5(1):e006450. doi: 10.1136/bmjopen-2014-006450.
- Yan D, Afifi L, Jeon C, Cordoro KM, Liao W. A cross-sectional study of the distribution of psoriasis subtypes in different ethno-racial groups. Dermatol Online J. 2018;24(7). 10.5070/D3247040909.
- Falto-Aizpurua LA, Martin-Garcia RF, Carrasquillo OY, et al. Biological therapy for pustular psoriasis: a systematic review. Int J Dermatol. 2020;59(3):284–296. doi: 10.1111/ijd.14671.
- Gooderham MJ, Van Voorhees AS, Lebwohl MG. An update on generalized pustular psoriasis. Expert Rev Clin Immunol. 2019;15(9):907–919. doi: 10.1080/1744666X.2019.1648209.
- Fujita H, Terui T, Hayama K, et al. Japanese guidelines for the management and treatment of generalized pustular psoriasis: the new pathogenesis and treatment of GPP. J Dermatol. 2018;45(11):1235–1270. doi: 10.1111/1346-8138.14523.
- Weir N, Athwal D, Brown D, et al. A new generation of high-affinity humanized PEGylated Fab' fragment anti-tumor necrosis factor-α monoclonal antibodies. Therapy. 2006;3(4):535–546.
- Mariette X, Förger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018;77(2):228–233. doi: 10.1136/annrheumdis-2017-212196.
- Pharmaceuticals and Medical Devices Agency. Available at (in Japanese). Accessed July 2021.
- Umezawa Y, Sakurai S, Hoshii N, Nakagawa H. Certolizumab pegol for the treatment of moderate to severe plaque psoriasis: 16-week results from a phase 2/3 Japanese study. Dermatol Ther (Heidelb) 2021;11(2):513–528. doi: 10.1007/s13555-021-00494-z.
- Umezawa Y, Asahina A, Imafuku S, et al. Efficacy and safety of certolizumab pegol in japanese patients with moderate to severe plaque psoriasis: 52-week results. Dermatol Ther (Heidelb) 2021;11(3):943–960. doi: 10.1007/s13555-021-00520-0.
- Gordon K, Warren RB, Gottlieb AB, et al. Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: three-year results from two randomised Phase 3 trials (CIMPASI-1 and CIMPASI-2) Br J Dermatol. 2021 doi: 10.1111/bjd.19393.
- Blauvelt A, Paul C, Kerkhof PVD, et al. Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase 3, randomised, placebo-controlled studies. Br J Dermatol. 2020 doi: 10.1111/bjd.19314.
- Criteria Committee, New York Heart Association . Diseases of the heart and blood vessels: nomenclature and criteria for diagnosis. 6. Boston: Little, Brown and Co; 1964. p. 114.
- Marrakchi S, Guigue P, Renshaw BR, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med. 2011;365(7):620–628. doi: 10.1056/NEJMoa1013068.
- Onoufriadis A, Simpson MA, Pink AE, et al. Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am J Hum Genet. 2011;89(3):432–437. doi: 10.1016/j.ajhg.2011.07.022.
- Bachelez H, Choon SE, Marrakchi S, et al. Trial of spesolimab for generalized pustular psoriasis. N Engl J Med. 2021;385(26):2431–2440. doi: 10.1056/NEJMoa2111563.
- Clowse ME, Förger F, Hwang C, et al. Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study. Ann Rheum Dis. 2017;76(11):1890–1896. doi: 10.1136/annrheumdis-2017-211384.
- Trivedi MK, Vaughn AR, Murase JE. Pustular psoriasis of pregnancy: current perspectives. Int J Womens Health. 2018;10:109–115. doi: 10.2147/IJWH.S125784.
- Johansen CB, Egeberg A, Jimenez-Solem E, Skov L, Thomsen SF. Psoriasis and adverse pregnancy outcomes: a nationwide case-control study in 491,274 women in Denmark. JAAD Int. 2022;7:146–155. doi: 10.1016/j.jdin.2022.03.009.
- Morita A, Yamazaki F, Matsuyama T, et al. Adalimumab treatment in Japanese patients with generalized pustular psoriasis: results of an open-label phase 3 study. J Dermatol. 2018;45(12):1371–1380. doi: 10.1111/1346-8138.14664.
- Saeki H, Nakagawa H, Nakajo K, et al. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52-week, open-label, phase 3 study (UNCOVER-J) J Dermatol. 2017;44(4):355–362. doi: 10.1111/1346-8138.13622.
- Okubo Y, Mabuchi T, Iwatsuki K, et al. Long-term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open-label, phase 3 study (UNCOVER-J) J Eur Acad Dermatol Venereol. 2019;33(2):325–332. doi: 10.1111/jdv.15287.
- Sano S, Kubo H, Morishima H, et al. Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study. J Dermatol. 2018;45(5):529–539. doi: 10.1111/1346-8138.14294.
- Saeki H, Nakagawa H, Ishii T, et al. Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis. J Eur Acad Dermatol Venereol. 2015;29(6):1148–1155. doi: 10.1111/jdv.12773.
- Curtis JR, Mariette X, Gaujoux-Viala C, et al. Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn's disease: a pooled analysis of 11 317 patients across clinical trials. RMD Open. 2019;5(1):e000942. doi: 10.1136/rmdopen-2019-000942.
- Gordon K, Papp K, Poulin Y, et al. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. J Am Acad Dermatol. 2012;66(2):241–251. doi: 10.1016/j.jaad.2010.12.005.
- Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366(9494):1367–1374. doi: 10.1016/S0140-6736(05)67566-6.
- Tyring S, Gordon KB, Poulin Y, et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol. 2007;143(6):719–726. doi: 10.1001/archderm.143.6.719.
- Imafuku S, Honma M, Okubo Y, et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52-week analysis from phase III open-label multicenter Japanese study. J Dermatol. 2016;43(9):1011–1017. doi: 10.1111/1346-8138.13306.
- Yamasaki K, Nakagawa H, Kubo Y, Ootaki K. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study. Br J Dermatol. 2017;176(3):741–751. doi: 10.1111/bjd.14702.
Source: PubMed